This profile has not been claimed and data may not be accurate.
88th percentile
82nd percentile
Founder and Chairperson of Biocon, India's largest listed biopharma company
Credibility
Traction · 91th percentile
- Biocon IPO'd on the Bombay Stock Exchange in 2004 and currently carries a market cap of approximately INR 327.7B (~$4B USD), making it one of India's largest listed biopharma groups.
Relationship Matrix
Most Like You
Most Complimentary
Founder score
- 99%Probability of being accurate (99%)Current founder and Executive Chairperson of Biocon Limited, which she founded in 1978 and continues to lead today.
- 99%Probability of being accurate (99%)Wikipedia entity exists for Kiran Mazumdar-Shaw, confirming strong public notability.
- 95%Probability of being accurate (95%)biocon.com ranks #181,220 on the Majestic Million (global domain prominence).
- 92%Probability of being accurate (92%)Biocon IPO'd on the Bombay Stock Exchange in 2004 and currently carries a market cap of approximately INR 327.7B (~$4B USD), making it one of India's largest listed biopharma groups.
- 75%Probability of being accurate (75%)Identified as a researcher on OpenAlex with an h-index of 5 and 131 citations across 13 works in healthcare and public health.
- 65%Probability of being accurate (65%)Biocon was co-founded with early partners, confirming the company had co-founders.
Investor score
- 90%Probability of being accurate (90%)Publicly identified as an angel investor with a portfolio of 8 companies, including investments in Bugworks Research, Gytree, 3one4 Capital, Strand Life Sciences, and Glympse Bio.
- 90%Probability of being accurate (90%)Portfolio exit: Strand Life Sciences was acquired for $34.9M.
- 90%Probability of being accurate (90%)Portfolio exit: Glympse Bio was acquired for $79.4M.
- 88%Probability of being accurate (88%)Has made 8 active investments across her angel portfolio, including life sciences and enterprise applications.
- 75%Probability of being accurate (75%)Has been an active investor since approximately 2010, representing roughly 14 years of investing experience.
What you likely need
You'd get the most from Festival events that connect you with global institutional and ESG investors who can amplify the Biocon Biologics biosimilar story, and with fellow Giving Pledge signatories who could co-invest in Indian public health infrastructure. Intimate roundtables with first-generation Indian biotech founders would let you deploy your garage-to-IPO credibility in a high-leverage, structured way. Strategic dinners with global pharma BD leaders and life sciences family office operators would help you formalize your angel activity and unlock co-investment partnerships.
Would you attend these IRL Festival events?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- positioningA dinner with ESG-focused institutional investors and global health-mandate fund managers to pressure-test the Biocon Biologics biosimilar insulin capacity expansion as a flagship emerging-markets ESG narrative
- introsA Giving Pledge signatory roundtable with fellow billionaire philanthropists — think Gates Foundation-aligned operators and Wellcome Trust LPs — exploring co-investment structures for Indian public health infrastructure alongside commercial biopharma interests
- introsA mentorship dinner for 6-8 first-generation Indian biotech founders at pre-Series A stage, structured around your Biocon garage-to-IPO arc as the anchoring case study
- fundraisingA small roundtable with Indian life sciences micro-VC and family office operators — think Quadria Capital and Omnivore-adjacent GPs — to pressure-test the structure and LP base for a formalized Kiran Mazumdar-Shaw angel fund
- tacticalA closed-door dinner with BD and supply chain leaders from global pharma companies actively seeking biosimilar manufacturing capacity post-Novo Nordisk's insulin production pullback
- tacticalA candid roundtable with IR advisors and public-market biopharma investors who have navigated founder-to-professional-CEO transitions — think Regeneron and Genentech alumni — to sharpen Biocon's public succession narrative
- positioningA dinner with editors and senior contributors from The Lancet, Health Affairs, and BMJ Global Health to map a publication strategy that positions you as a primary voice on biosimilar affordability and regulatory reform